Dr. Edward V. Loftus Jr. discusses the use of interchangeable biosimilars in patients with inflammatory bowel disease in a video exclusive for Healio. The availability of interchangeable biosimilars like Cyltezo, Abrilada, and Wezlana has increased access to costly medications for patients. Dr. Loftus explains that interchangeable biosimilars have been studied more than regular biosimilars and can be switched from the reference product without the prescriber’s knowledge in some states. While there are concerns about switching between interchangeable biosimilars, the approval process is reliable and benefits the healthcare system by providing less expensive alternatives to originator drugs.
Source link
Concerns linger for interchangeable biosimilar switch ‘without prescriber knowing’
